BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28303362)

  • 41. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
    Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
    Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
    Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
    Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
    Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
    Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K
    Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
    Sym SJ; Chang HM; Kang HJ; Lee SS; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):1-8. PubMed ID: 18288477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
    Maeda O; Matsuoka A; Miyahara R; Funasaka K; Hirooka Y; Fukaya M; Nagino M; Kodera Y; Goto H; Ando Y
    World J Gastroenterol; 2017 Feb; 23(6):1090-1097. PubMed ID: 28246483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
    Iwasa S; Goto M; Yasui H; Nishina T; Takahari D; Nakayama N; Taira K; Kusaba H; Fuse N; Hironaka S; Shimada Y; Nakajima TE
    Jpn J Clin Oncol; 2012 Sep; 42(9):787-93. PubMed ID: 22782960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
    Kang YK; Kang WK; Shin DB; Chen J; Xiong J; Wang J; Lichinitser M; Guan Z; Khasanov R; Zheng L; Philco-Salas M; Suarez T; Santamaria J; Forster G; McCloud PI
    Ann Oncol; 2009 Apr; 20(4):666-73. PubMed ID: 19153121
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.
    Thuss-Patience PC; Kretzschmar A; Dogan Y; Rothmann F; Blau I; Schwaner I; Breithaupt K; Bichev D; Grothoff M; Grieser C; Reichardt P
    Br J Cancer; 2011 Aug; 105(4):505-12. PubMed ID: 21792201
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
    Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
    J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
    Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
    Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
    Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
    Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.